COMPLETED

The Anabolic Properties of a Lipid-rich Pork Matrix

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The amount and quality of skeletal muscle mass determines physical performance, but also a significant contributor to metabolic health. As such, the maintenance of skeletal muscle mass is relevant across the lifespan to remain active in family and community life. Food ingestion, particularly protein, is one of the main anabolic to skeletal muscle tissue by stimulating muscle protein synthesis rates. There have been multiple attempts to identify specialized performance nutrition products (e.g., various isolated protein powders) to maximize the anabolic properties of dietary protein on muscle. Our research group, however, has advocated for a food focus approach to meet dietary protein requirements. Particularly, we propose that whole foods demonstrate food matrix effects (nutrient-nutrient interactions) that creates a greater anabolic action on muscle beyond what amino acids can create alone. Therefore, the objective of this study is to identify the anabolic properties of consuming lipid-rich pork products when compared to their leaner counter-parts. Our working hypothesis that the ingestion of 84% or 96% lean ground pork condition will stimulate a greater increase in muscle protein synthesis rates compared to an isocaloric carbohydrate beverage in healthy adults. We further hypothesize that the ingestion of 84% lean pork will augment the stimulation of muscle protein synthesis rates to a greater extent than 96% lean ground pork. To achieve our objective, we will recruit 15 healthy men and women (20-50 y) to receive prime-constant infusions to directly measure muscle protein synthesis rates before and after treatment ingestion using our lab's established methods.

Official Title

The Anabolic Properties of a Lipid-rich Pork Matrix

Quick Facts

Study Start:2023-07-15
Study Completion:2024-04-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05876299

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:20 Years to 50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 20-50 yrs
  2. * Pre-menopausal
  3. * Recreationally active
  4. * Weight stable for prior 6 months
  1. * Age outside of range (20 - 50 yrs)
  2. * Pregnancy
  3. * Irregular menstrual cycles
  4. * Participation in previous research using \[13C6\]phenylalanine
  5. * Participation in other ongoing research that interferes with this study (e.g., conflicting diet, activity interventions, etc.)
  6. * Any hospitalization or surgery for a metabolic, cardiovascular, or neuromusculoskeletal complication within the past year
  7. * Allergy or hypersensitivity to local anesthetics, latex, or adhesives (bandages, medical tape, etc.)
  8. * Excess scarring after injury
  9. * History of excess bleeding after cut
  10. * Chronic or frequent dizziness/fainting, and arm or leg weakness/numbness
  11. * Arthritis
  12. * Tumors
  13. * Mental Illness
  14. * Hepatorenal, cardiovascular musculoskeletal, autoimmune, or neurological disease or disorder
  15. * Predisposition to hypertrophic scarring or keloid formation
  16. * Physical activity limitations
  17. * Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  18. * Consumption of thyroid, androgenic, or other medications known to affect endocrine function
  19. * Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
  20. * Unwillingness to comply with study procedures
  21. * Weight unstable (variation \>5% of bodyweight in last 6-12 months)
  22. * Current or previous tobacco use with last 6 months
  23. * Obesity (body mass index; BMI \> 30 kg/m\^2)
  24. * Score of less than 14 or greater than 24 on Godin-Shephard Leisure-Time Physical Activity Questionnaire
  25. * Phenylketonuria
  26. * Anyone hospitalized previously for COVID-19 without a cardiovascular workup screening for cardiovascular issues post-infection
  27. * Anyone recovering from COVID-19 infection within the preceding 10 days

Contacts and Locations

Principal Investigator

Nicholas A Burd, PhD
PRINCIPAL_INVESTIGATOR
University of Illinois at Urbana-Champaign

Study Locations (Sites)

Louise Freer Hall (University of Illinois Urbana-Champaign)
Urbana, Illinois, 61801
United States

Collaborators and Investigators

Sponsor: University of Illinois at Urbana-Champaign

  • Nicholas A Burd, PhD, PRINCIPAL_INVESTIGATOR, University of Illinois at Urbana-Champaign

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-15
Study Completion Date2024-04-09

Study Record Updates

Study Start Date2023-07-15
Study Completion Date2024-04-09

Terms related to this study

Additional Relevant MeSH Terms

  • Muscle Protein Synthesis